We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
-1.35%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$206M
AUM Growth
+$10.1M
Cap. Flow
+$39M
Cap. Flow %
18.95%
Top 10 Hldgs %
63.37%
Holding
47
New
7
Increased
9
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$14.9M
2
VSTM icon
Verastem
VSTM
+$10.7M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.1M
4
REPL icon
Replimune Group
REPL
+$7.3M
5
NUVB icon
Nuvation Bio
NUVB
+$5.58M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$10.6M
2
OPTN
OptiNose
OPTN
+$3.9M
3
VRNA
Verona Pharma
VRNA
+$2.99M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$2.46M
5
MDWD icon
MediWound
MDWD
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Miscellaneous 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
26
Cogent Biosciences
COGT
$5.72B
$1.49M 0.72%
+248,285
New +$1.95M
TLPH icon
27
Talphera
TLPH
$61.2M
$992K 0.48%
2,003,939
+1,390,000
+226% +$847K
KPRX icon
28
Kiora Pharmaceuticals
KPRX
$11.5M
$753K 0.37%
250,059
-496
-0.2% -$1.72K
KURA icon
29
Kura Oncology
KURA
$1.02B
$660K 0.32%
+100,000
New +$779K
ACOG
30
Alpha Cognition
ACOG
$188M
$530K 0.26%
104,836
-147,917
-59% -$863K
BFRI icon
31
Biofrontera
BFRI
$18.3M
$516K 0.25%
644,393
-167,525
-21% -$172K
QQQ icon
32
PUT
Invesco QQQ Trust
QQQ
$477B
$374K 0.18%
50,000
-50,000
-50% -$25.4M
LXRX icon
33
CALL
Lexicon Pharmaceuticals
LXRX
$908M
$30K 0.01%
1,278,900
– –
CADL icon
34
PUT
Candel Therapeutics
CADL
$868M
$3.57K ﹤0.01%
15,800
-246,700
-94% -$2.02M
BMEA icon
35
PUT
Biomea Fusion
BMEA
$132M
– –
-910,700
Closed -$2.76M
CRMD icon
36
CALL
CorMedix
CRMD
$605M
– –
-183,900
Closed -$920K
EWTX icon
37
PUT
Edgewise Therapeutics
EWTX
$4.86B
– –
-237,500
Closed -$808K
NMRA icon
38
PUT
Neumora Therapeutics
NMRA
$162M
– –
-136,600
Closed -$300K
OEF icon
39
PUT
iShares S&P 100 ETF
OEF
$20.2B
– –
-200,000
Closed -$404K
OWLT icon
40
Owlet
OWLT
$137M
– –
-49,441
Closed -$220K
RLMD icon
41
Relmada Therapeutics
RLMD
$473M
– –
-100,000
Closed -$52K
RLMD icon
42
PUT
Relmada Therapeutics
RLMD
$473M
– –
-100,000
Closed -$95K
FLNA
43
Filana Therapeutics
FLNA
$32.9M
– –
-417,400
Closed -$985K
FLNA
44
PUT
Filana Therapeutics
FLNA
$32.9M
– –
-417,400
Closed -$3.65M
XNTK icon
45
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.89B
– –
-1,400,000
Closed -$22K
XNTK icon
46
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.89B
– –
-800,000
Closed -$311K
CMRX
47
DELISTED
Chimerix, Inc.
CMRX
– –
-3,050,000
Closed -$10.6M
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.18% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Rosalind Advisors held 47 positions worth $206M, up 5.1% from $196M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Rosalind Advisors deployed $39M of net new capital in Q1 2025, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was IDEAYA Biosciences: 700,000 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was OptiNose, an estimated $3.9M trimmed.

  • Rosalind Advisors's largest Q1 2025 buy was IDEAYA Biosciences: 700,000 shares worth $11.5M.
  • Rosalind Advisors added most to Verastem in Q1 2025, an estimated $10.7M increase.
  • Rosalind Advisors's biggest Q1 2025 reduction was OptiNose, cutting an estimated $3.9M.
  • Rosalind Advisors fully exited Chimerix, Inc. in Q1 2025, selling an estimated $10.6M.
  • Rosalind Advisors's ten largest holdings make up 63% of its $206M portfolio in Q1 2025.
  • Rosalind Advisors opened 7 new positions and closed 13 in Q1 2025.
  • Rosalind Advisors's portfolio value rose 5.1% quarter-over-quarter to $206M.

Based on Rosalind Advisors's 13F filing for Q1 2025, filed 14 May 2025.